| abstract |
The present invention relates to modified proteins and peptides that have a reduced ability to bind pre-existing antibodies. Such modified protein/peptide molecules may contain C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (e.g. fusions and conjugates) comprise proteins, peptides, antigen binding molecules, antibodies or antibody fragments such as single variable domains, e.g. human immunoglobulin (antibody) single variable domains, and Single variable domains, such as VHHs, derived from non-human sources such as llamas or camels, including nanobodies™ (such as described, inter alia, in WO 94/04678 and WO 95/04079). The present invention further relates to uses, formulations, compositions of molecules comprising such modified C-terminal extensions and/or amino acid substitutions, and also to methods of production and expression of these molecules. |